FDA Approves Rybelsus, First Oral GLP-1 Medicine

The U.S. Food and Drug Administration (FDA) has approved the first oral GLP-1 medicine for blood sugar management in adults with type 2 diabetes. Manufactured by Novo Nordisk, Rybelsus (semaglutide) oral tablets are the first drug in their class that do not need to be injected.

To get cutting-edge diabetes news, strategies for blood glucose management, nutrition tips, healthy recipes, and more delivered straight to your inbox, sign up for our free newsletter[1]!

A member of the class of medicines known as GLP-1 inhibitors[2], it works by increasing feelings of fullness, slowing stomach emptying, increasing the release of insulin, and decreasing the release of glucagon[3] (a hormone that raises blood glucose).

Rybelsus is approved for once-daily use[4] in 7-milligram or 14-milligram doses and is expected to be available in the United States in the fourth quarter of 2019. According to the manufacturer, “A savings card program will be available at the time of launch for eligible commercially-insured patients to keep out of pocket costs down to as little as $10 a month.”

“Patients want effective treatment options for diabetes that are as minimally intrusive on their lives as possible, and the FDA welcomes the advancement of new therapeutic options that can make it easier for patients to control their condition,” noted Lisa Yanoff, MD[5], acting director of the Division of Metabolism and Endocrinology Products in the FDA’s Center for Drug Evaluation and Research. “Before this approval, patients did not have an oral GLP1 option to treat their type 2 diabetes, and now patients will have a new option for treating type 2 diabetes without injections.”


To learn more about Rybelsus, read the press releases from the FDA[6] or Novo Nordisk.[7]

Want to learn more about the GLP-1 inhibitor class of medicines? Read “Non-Insulin Injectable Diabetes Medicines.”[8]

Diane Fennell[9]

Diane Fennell

Editorial Director of the Wellness Division, Fennell has 16 years’ experience specializing in diabetes and related health conditions. Based in New York City, she has a degree from Columbia University.

  1. sign up for our free newsletter: https://dsm.diabetesselfmanagement.com/newsletter/
  2. GLP-1 inhibitors: https://dsm.diabetesselfmanagement.com/blog/non-insulin-injectable-diabetes-medications/
  3. glucagon: https://dsm.diabetesselfmanagement.com/diabetes-resources/definitions/glucagon/
  4. once-daily use: https://www.novonordisk-us.com/media/news-releases.html?122973
  5. noted Lisa Yanoff, MD: https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-glp-1-treatment-type-2-diabetes
  6. the FDA: https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-glp-1-treatment-type-2-diabetes
  7. Novo Nordisk.: https://www.novonordisk-us.com/media/news-releases.html?122973
  8. “Non-Insulin Injectable Diabetes Medicines.”: https://dsm.diabetesselfmanagement.com/blog/non-insulin-injectable-diabetes-medications/
  9. [Image]: //cdn.diabetesselfmanagement.com/2019/06/DFennell-Headshot.jpg

Source URL: https://dsm.diabetesselfmanagement.com/blog/fda-approves-rybelsus-first-oral-glp-1-medicine/

Diane Fennell: Diane Fennell has been an editor at Diabetes Self-Management magazine since 2003. She is currently the Editorial Director. (Diane Fennell is not a medical professional.)

Disclaimer of Medical Advice: You understand that the blog posts and comments to such blog posts (whether posted by us, our agents or bloggers, or by users) do not constitute medical advice or recommendation of any kind, and you should not rely on any information contained in such posts or comments to replace consultations with your qualified health care professionals to meet your individual needs. The opinions and other information contained in the blog posts and comments do not reflect the opinions or positions of the Site Proprietor.